UK consensus on normal tissue dose constraints for stereotactic radiotherapy
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ...
主要な著者: | Hanna, G, Murray, L, Patel, R, Jain, S, Aitken, K, Franks, K, van As, N, Tree, A, Hatfield, P, Harrow, S, McDonald, F, Ahmed, M, Saran, F, Webster, G, Khoo, V, Landau, D, Eaton, D, Hawkins, M |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Elsevier
2017
|
類似資料
-
UK stereotactic ablative radiotherapy trials normal tissue dose constraints tolerance consensus
著者:: Hanna, G, 等
出版事項: (2016) -
Stereotactic body radiotherapy for liver metastases.
著者:: Aitken, K, 等
出版事項: (2015) -
Stereotactic body radiotherapy for oligometastases.
著者:: Tree, A, 等
出版事項: (2013) -
A randomised trial of conventional care versus radioablation (stereotactic body radiotherapy) for extracranial oligometastases
著者:: Khoo, V, 等
出版事項: (2018) -
CORE: A randomised trial of COnventional care versus radioablation (stereotactic body radiotherapy) for extracranial oligometastases
著者:: Khoo, V, 等
出版事項: (2017)